April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
Pegaptanib Sodium for Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO)
Author Affiliations & Notes
  • B. S. Rosen
    Ophthalmology, SC Permanente Physicians Group, West Los Angeles, California
  • D. J. Sassoon
    Ophthalmology, SC Permanente Physicians Group, West Los Angeles, California
  • A. T. Bui
    Ophthalmology, SC Permanente Physicians Group, West Los Angeles, California
  • Footnotes
    Commercial Relationships  B.S. Rosen, Eyetech, R; D.J. Sassoon, None; A.T. Bui, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 4739. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      B. S. Rosen, D. J. Sassoon, A. T. Bui; Pegaptanib Sodium for Macular Edema Secondary to Branch Retinal Vein Occlusion (BRVO). Invest. Ophthalmol. Vis. Sci. 2010;51(13):4739.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Intravitreal pegaptanib administered every 6 weeks has provided improvements in visual acuity and central retinal thickness in an independent study in patients with BRVO. This case series presents the effectiveness of pegaptanib to treat macular edema secondary to retinal vascular occlusion in a clinical setting.

Methods: : This was a retrospective analysis of consecutive patients with BRVO presenting to two retina practices and who were treated with intravitral injections of 0.3 mg pegaptanib sodium. Assessments included complete ocular examination, Snellen visual acuity (VA; converted to logMAR for analyses) and optical coherence tomography.

Results: : To date, 11 eyes of 11 patients with BRVO received a mean of 4.5±2.7 intravitral injections of pegaptanib over a course of 6.8±5.6 months. Eight (73%) were female and 5 (45%) had hypertension. The mean VA improved from 0.68±0.25 (≈20/100) at baseline to 0.40± 0.34(≈20/50) at month 6, and mean center point thickness decreased from 326 microns to 254 microns; gains of ≥3 and ≥0 lines of vision occurred in 45% and 82% patients, respectively, and 91% lost <3 lines during 6 months of follow-up. Additional data will be provided.

Conclusions: : In this small case series, promising visual and anatomical results were seen with pegaptanib in patients with BRVO. We emphasize that this and other relatively small studies are inadequately powered to address questions of systemic safety, which remain unanswered. Phase 3 trials are indicated to confirm the potential benefit of pegaptanib in patients.

Keywords: retina • vascular occlusion/vascular occlusive disease • vascular endothelial growth factor 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×